{"id":"W3159131528","doi":"10.1080/09546634.2021.1902925","title":"Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study","year":2021,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; SKiN Health; University of British Columbia","funders":"","keywords":"Secukinumab; Medicine; Tolerability; Placebo; Psoriasis Area and Severity Index; Psoriasis; Bioequivalence; Randomized controlled trial; Clinical endpoint; Adverse effect; Internal medicine; Pharmacokinetics; Dermatology; Psoriatic arthritis; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006083559,0.0005290916,0.002102716,0.0001114248,0.0002818576,0.00009964107,0.0001506153,0.0002416566,0.00006138479],"category_scores_gemma":[0.0002704932,0.0002447425,0.0002585384,0.000212773,0.0001369998,0.0001699793,0.00009340708,0.0003425778,0.000006207189],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000310477,"about_ca_system_score_gemma":0.0001891461,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002864468,"about_ca_topic_score_gemma":0.001441931,"domain_scores_codex":[0.9951891,0.002260805,0.001291594,0.0006209064,0.0002287815,0.0004087642],"domain_scores_gemma":[0.9958519,0.002535762,0.000765473,0.000419679,0.0003107374,0.0001164085],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8269011,0.0062042,0.1488339,0.000004536539,0.003790855,0.0003510813,0.005759905,0.0007568474,0.00003669092,0.000007868303,0.00001349705,0.007339481],"study_design_scores_gemma":[0.8965256,0.007527519,0.09103356,0.0001472,0.001526776,0.0002924743,0.001770476,0.00002867941,0.0007960154,0.00003171839,0.00003753315,0.000282474],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992868,0.0007126754,0.00005117909,0.0008486011,0.0002020644,0.005109025,0.0001407225,0.00002588284,0.00004186237],"genre_scores_gemma":[0.9989207,0.00007190505,0.0002749345,0.0000828172,0.00002845498,0.0004692168,0.0001140968,0.00001941579,0.00001848447],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06962448,"threshold_uncertainty_score":0.9980309,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02362595623354314,"score_gpt":0.2691566812626643,"score_spread":0.2455307250291212,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}